Several new imidazole and triazole antifungal agents have been developed in the last few years. These are effective topically in the treatment of vaginal candidiasis and dermatophytosis, but only ketoconazole is effective orally (p.o.) against these infections (5, 11) . Ketoconazole has shown variable activity on evaluation against life-threatening systemic infections (12) ; the drug of choice for treating these infections is the polyene amphotericin B, the use of which is limited by toxicity and the need to give it by intravenous (i.v.) infusion. We recently succeeded in developing UK-49,858 ( Fig. 1) , a new bis-triazole derivative, which combines high oral efficacy with water solubility. In this report we compare its activity with that of ketoconazole against experimental superficial infections with Candida albicans in mice and Trichophyton mentagrophytes in guinea pigs and against systemic C. albicans infections in mice and rats, including mice with impaired defense mechanisms.
MATERIALS AND METHODS
Fungi. All fungi used in these studies were 
DISCUSSION
Human fungal diseases can be divided into the life-threatening systemic infections and the more common superficial ones. The life-threatening fungal infections are a growing and universal problem, primarily among immunosuppressed patients (15) , and the few drugs currently available have limited efficacy or are poorly tolerated (11, 12) .
The most common superficial infections are the dermatophytoses and vaginal candidiasis, and although many topical preparations are available, these are frequently inconvenient to use; there is therefore a need for a safe, orally effective agent. In the present study, UK-49,858 showed several advantages over currently used systemic agents. It exerted superior protection to that of ketoconaiole in mice or rats with lethal C. albicans infections and was equipotent by p.o. or i.v. dosing. In addition, UK-49,858 maintained its efficacy in immunosuppressed animals, which suggests that it may be of value for treating systemic C. albicans infections in patients with immune system dysfunction.
Although oral agents are usually most convenient, parenteral therapy may be necessary in immediately postoperative patients or in those with drug-induced malabsorption (J. therapeutic dose regimes. Ketoconazole shows better efficacy in a rat vaginal candidiasis model (8, 9, 14) than in the mouse model, and published data do suggest that azoles are less efficacious in the mouse model (3, 8, 14) . However, both models have some predictive value for human efficacy. As a 5-day course of ketoconazole is effective in women with vaginal candidiasis, our data suggest that short-term oral therapy with UK-49,858 may also be effective in this indication.
Trichophytosis in guinea pigs is a well-established predictive model for testing topical (5-7) and systemic antifunigal agents (7, 13, 14) . Published data from studies with animals show that p.o. ketoconazole gives cure rates of at least 80% at doses between 20 and 60 mg/kg and are consistent with the findings in this study. The >80% cure rate at 5 mg/kg with UK-49,858 indicates its superiority over ketoconazole in this model system and suggests that it may show superior efficacy against dermatophytosis in humans.
The results presented in this paper indicate that p.o. UK-49,858 possesses superior activity to that of ketoconazole in a range of animal models of systemic and superficial fungal infections, Its activity after parenteral administration approaches that of amphotericin B. In addition, it has a wider spectrum of antifungal action than does either 5-fluorocytosine or griseofulvin. This activity profile plus its aqueous solubility suggests that UK-49,858 may have poten- 
